NEWLINK GENETICS CORPORATION

94 Jackson Rd Ste 108, Devens, Massachusetts, United States

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

55.9%

Phase 2

32.4%

Phase 3

5.9%

Early Phase 1

2.9%

Trial Status Distribution

Completed

55.9%

Terminated

41.2%

Withdrawn

2.9%

Clinical Trials

Trials sponsored by this organization (34)

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers

Early Phase 1

Completed

interventional

Mar 201856 participants

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma

Phase 2

Terminated

interventional

Dec 201721 participants

Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers

Phase 1

Completed

interventional

Nov 201748 participants

Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

Terminated

observational

Sep 201729 participants

NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Phase 1

Completed

interventional

Jun 201726 participants

A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1

Completed

interventional

Jul 201654 participants

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Phase 1

Terminated

interventional

Jan 201616 participants

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Phase 1

Terminated

interventional

Oct 201541 participants

Page 1 of 5

Approvals

No approval data available

News

No news articles found

Back to Organizations